期刊
MICROORGANISMS
卷 10, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/microorganisms10071298
关键词
human African trypanosomiasis; animal African trypanosomiasis; antitrypanosomal drugs; drugs mechanism of action; one health approaches
类别
资金
- European Commission [603240]
- FCT [2020.07306, POCI-01-0145-FEDER-031013 (PTDC/SAU-PAR/31013/2017)]
Human African Trypanosomiasis (HAT) and Animal African Trypanosomiasis (AAT) are tropical diseases caused by the same pathogen. Despite progress in controlling HAT, AAT remains a reservoir of infection. Clearer guidelines are needed to address the challenges of drug use and resistance development.
Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reservoir of the infections. There is a strong need to control AAT, as is claimed by the European Commission in a recent document on the reservation of antimicrobials for human use. Control of AAT is considered part of the One Health approach established by the FAO program against African Trypanosomiasis. Under the umbrella of the One Health concepts, in this work, by analyzing the pharmacological properties of the therapeutic options against Trypanosoma brucei spp., we underline the need for clearer and more defined guidelines in the employment of drugs designed for HAT and AAT. Essential requirements are addressed to meet the challenge of drug use and drug resistance development. This approach shall avoid inter-species cross-resistance phenomena and retain drugs therapeutic activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据